AR089634A1 - Nucleosidos carbociclicos y su uso y composiciones farmaceuticos - Google Patents
Nucleosidos carbociclicos y su uso y composiciones farmaceuticosInfo
- Publication number
- AR089634A1 AR089634A1 ARP130100018A ARP130100018A AR089634A1 AR 089634 A1 AR089634 A1 AR 089634A1 AR P130100018 A ARP130100018 A AR P130100018A AR P130100018 A ARP130100018 A AR P130100018A AR 089634 A1 AR089634 A1 AR 089634A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- alkynyl
- cycloalkyl
- alkenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052711 selenium Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
También se describen procesos para la preparación de dichos compuestos, intermedios usados en la preparación de dichos compuestos y los usos de dichos compuestos para tratar enfermedades inflamatorias de la piel. Reivindicación 1: Un compuesto de la fórmula (1) donde R¹ y R² se seleccionan independientemente de hidrógeno, CO₂-alquilo C₁₋₄, alquilo C₁₋₆, alquenilo C₂₋₆ y alquinilo C₂₋₆, donde los restos alquilo de dichos grupos alquilo, alquenilo y alquinilo pueden ser de cadena lineal, ramificada o una combinación de cadena lineal y ramificada de fórmula (2) donde n es 0 a 3, de fórmula (3) donde n es 1 a 2, cicloalquilo C₃₋₇, un anillo heterocíclico de tres a doce miembros que contiene hasta 3 heteroátomos donde los heteroátomos se seleccionan independientemente de N, O y S y donde cada anillo heterocíclico puede estar opcionalmente sustituido en uno o más átomos de carbono por 1 a 3 sustituyentes que se seleccionan independientemente de alcoxi C₁₋₆ y O-alquilo C₁₋₆; R³ y R⁴ se seleccionan independientemente de hidrógeno y alquilo C₁₋₆; R⁵ y R⁶ se seleccionan independientemente de hidrógeno y -CO₂C₄H₉; A se selecciona de un enlace covalente, O, S, Se, alquilo C₁₋₆ y (CH₂)ₙO, donde n es un entero de 0 a 3; X se selecciona de un enlace covalente, O, S y Se; B se selecciona de un enlace covalente, -CH₂, -CH₂-CH₂-, -CH₂-CH₂-CH₂-, trans-CH=CH-, cis-CH=CH-, -CºC-, -CHR⁷-CHR⁸-, cis o trans-CR⁷=CR⁸-, donde R⁷ y R⁸ se seleccionan independientemente alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆ y cicloalquilo C₃₋₇; e Y se selecciona de OH, SH, OR⁹ donde R⁹ es alquilo C₁₋₆, alquenilo C₂₋₆ y alquinilo C₂₋₆, cicloalquilo C₃₋₇ y -(CH₂)ₙOH, donde n es un entero de 1 a 6 y NR⁹R¹⁰ donde R⁹ y R¹⁰ se seleccionan independientemente de alquilo C₁₋₆ y cicloalquilo C₃₋₇; o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261582550P | 2012-01-03 | 2012-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR089634A1 true AR089634A1 (es) | 2014-09-03 |
Family
ID=47628435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100018A AR089634A1 (es) | 2012-01-03 | 2013-01-03 | Nucleosidos carbociclicos y su uso y composiciones farmaceuticos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8895569B2 (es) |
| EP (1) | EP2800750B1 (es) |
| JP (1) | JP5881864B2 (es) |
| KR (1) | KR101763740B1 (es) |
| CN (1) | CN104321323B (es) |
| AR (1) | AR089634A1 (es) |
| AU (1) | AU2012363635B2 (es) |
| BR (1) | BR112014016615A8 (es) |
| CA (1) | CA2862006C (es) |
| DK (1) | DK2800750T3 (es) |
| EA (1) | EA028518B1 (es) |
| ES (1) | ES2607069T3 (es) |
| HK (1) | HK1203496A1 (es) |
| IL (1) | IL233475A (es) |
| IN (1) | IN2014MN01507A (es) |
| MX (1) | MX2014008135A (es) |
| MY (1) | MY166057A (es) |
| SG (1) | SG11201404291TA (es) |
| TW (1) | TWI481611B (es) |
| WO (1) | WO2013103601A1 (es) |
| ZA (1) | ZA201405453B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017201179A1 (en) * | 2016-05-18 | 2017-11-23 | Innovation Pharmaceuticals Inc. | Methods of preparing carbocyclic nucleosides |
| WO2018230479A1 (ja) * | 2017-06-13 | 2018-12-20 | 大原薬品工業株式会社 | ヌクレオシド系抗がん剤又は抗ウィルス剤の５'位シリルエーテル誘導体 |
| CN111393444B (zh) * | 2019-01-02 | 2022-10-28 | 上海迪赛诺化学制药有限公司 | 一种阿巴卡韦羟基醋酸酯的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931559A (en) * | 1988-01-20 | 1990-06-05 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
| GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| GB8916478D0 (en) * | 1989-07-19 | 1989-09-06 | Glaxo Group Ltd | Chemical process |
| MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| AU2006326388B2 (en) * | 2005-12-14 | 2013-01-24 | Nuvo Research Inc. | Compositions and methods for treating dermatological conditions |
| EP1939196A1 (en) * | 2006-12-21 | 2008-07-02 | Esteve Quimica, S.A. | Process for the preparation of abacavir |
| US20100068786A1 (en) * | 2008-09-16 | 2010-03-18 | Chmielewski Jean A | Methods and compositions for reversing p-glycoprotein medicated drug resistance |
-
2012
- 2012-12-28 EP EP12819169.9A patent/EP2800750B1/en not_active Not-in-force
- 2012-12-28 JP JP2014551289A patent/JP5881864B2/ja not_active Expired - Fee Related
- 2012-12-28 CA CA2862006A patent/CA2862006C/en not_active Expired - Fee Related
- 2012-12-28 ES ES12819169.9T patent/ES2607069T3/es active Active
- 2012-12-28 TW TW101151185A patent/TWI481611B/zh not_active IP Right Cessation
- 2012-12-28 BR BR112014016615A patent/BR112014016615A8/pt not_active IP Right Cessation
- 2012-12-28 EA EA201400786A patent/EA028518B1/ru not_active IP Right Cessation
- 2012-12-28 MX MX2014008135A patent/MX2014008135A/es unknown
- 2012-12-28 MY MYPI2014001973A patent/MY166057A/en unknown
- 2012-12-28 SG SG11201404291TA patent/SG11201404291TA/en unknown
- 2012-12-28 US US13/730,247 patent/US8895569B2/en not_active Expired - Fee Related
- 2012-12-28 AU AU2012363635A patent/AU2012363635B2/en not_active Ceased
- 2012-12-28 KR KR1020147021716A patent/KR101763740B1/ko active IP Right Grant
- 2012-12-28 WO PCT/US2012/072103 patent/WO2013103601A1/en active Application Filing
- 2012-12-28 CN CN201280068468.3A patent/CN104321323B/zh not_active Expired - Fee Related
- 2012-12-28 DK DK12819169.9T patent/DK2800750T3/en active
-
2013
- 2013-01-03 AR ARP130100018A patent/AR089634A1/es unknown
-
2014
- 2014-07-01 IL IL233475A patent/IL233475A/en not_active IP Right Cessation
- 2014-07-23 ZA ZA2014/05453A patent/ZA201405453B/en unknown
- 2014-07-25 IN IN1507MUN2014 patent/IN2014MN01507A/en unknown
-
2015
- 2015-04-27 HK HK15104037.0A patent/HK1203496A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20140200229A1 (en) | 2014-07-17 |
| SG11201404291TA (en) | 2014-09-26 |
| IN2014MN01507A (es) | 2015-05-01 |
| KR20140123513A (ko) | 2014-10-22 |
| CN104321323B (zh) | 2016-10-12 |
| EP2800750A1 (en) | 2014-11-12 |
| BR112014016615A2 (pt) | 2017-06-13 |
| HK1203496A1 (en) | 2015-10-30 |
| US8895569B2 (en) | 2014-11-25 |
| AU2012363635A1 (en) | 2014-08-14 |
| CA2862006C (en) | 2016-10-25 |
| IL233475A (en) | 2017-09-28 |
| AU2012363635B2 (en) | 2015-07-23 |
| JP5881864B2 (ja) | 2016-03-09 |
| WO2013103601A1 (en) | 2013-07-11 |
| EA201400786A1 (ru) | 2014-12-30 |
| ES2607069T3 (es) | 2017-03-29 |
| DK2800750T3 (en) | 2017-02-27 |
| KR101763740B1 (ko) | 2017-08-01 |
| EP2800750B1 (en) | 2016-11-23 |
| IL233475A0 (en) | 2014-08-31 |
| ZA201405453B (en) | 2015-11-25 |
| MX2014008135A (es) | 2014-09-12 |
| JP2015504070A (ja) | 2015-02-05 |
| MY166057A (en) | 2018-05-22 |
| EA028518B1 (ru) | 2017-11-30 |
| BR112014016615A8 (pt) | 2017-07-04 |
| TW201333009A (zh) | 2013-08-16 |
| CN104321323A (zh) | 2015-01-28 |
| CA2862006A1 (en) | 2013-07-11 |
| TWI481611B (zh) | 2015-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR090847A1 (es) | Compuestos moduladores del receptor huerfano retinoideo (ror) | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR102362A1 (es) | Compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| AR095077A1 (es) | Lípidos y composiciones lípidas para la entrega de agentes activos | |
| AR090121A1 (es) | Compuestos de oxazolidin-2-ona y usos de los mismos | |
| AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR087052A1 (es) | Derivados de amina ciclica como antagonistas del receptor ep4 | |
| AR090945A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| CY1120378T1 (el) | Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης) | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| AR110498A1 (es) | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR104415A1 (es) | Compuestos antiestrogénicos derivados de cromeno | |
| AR087868A1 (es) | Compuestos de triazolopiridina como moduladores de la tirosina quinasa c-met | |
| AR097543A1 (es) | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR097545A1 (es) | COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO | |
| AR093035A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR094497A1 (es) | Compuestos tetracíclicos sustituidos con tiofeno y métodos de uso de los mismos para el tratamiento de enfermedades víricas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |